1. Hermsen JL, Nath DS, del Rio AM, Eickstaedt JB, Wigfield C, Lindsey JD, et al. Combined heart-kidney transplantation: the University of Wisconsin experience. J Heart Lung Transplant. 2007;26:1119–26.
2. Norman JC, Brook MI, Cooley DA, Klima T, Kahan BD, Frazier OH, et al. Total support of the circulation of a patient with post-cardiotomy stone-heart syndrome by a partial artificial heart (ALVAD) for 5 days followed by heart and kidney transplantation. Lancet. 1978;1:1125–7.
3. Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult heart transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant. 2017;36:1037–46.
4. Awad MA, Czer LSC, Emerson D, Jordan S, De Robertis MA, Mirocha J, et al. Combined heart and kidney transplantation: clinical experience in 100 consecutive patients. J Am Heart Assoc. 2019;8. DOI: 10.1161/JAHA.118.010570.
5. Blanche C, Kamlot A, Blanche DA, Kearney B, Wong AV, Czer LS, et al. Combined heart-kidney transplantation with single-donor allografts. J Thorac Cardiovasc Surg. 2001;122:495–500.
6. Trachiotis GD, Vega JD, Johnston TS, Berg A, Whelchel J, Smith AL, et al. Ten-year follow-up in patients with combined heart and kidney transplantation. J Thorac Cardiovasc Surg. 2003;126:2065–71.
7. Wang S, Chou N, Chi N, Hsu R, Huang S, Chen Y, et al. Simultaneous heart and kidney transplantation for combined cardiac and renal failure. Transplant Proc. 2006;38:2135–7.
8. Mc Loughlin S, Bianco JC, Marenchino RG. Anesthetic and perioperative considerations for combined heart-kidney transplantation. J Cardiothorac Vasc Anesth. 2018;32:44–9.
9. Kim HY, Lee JE, Kim HY, Kim J. Volatile sedation in the intensive care unit: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96. DOI: 10.1097/MD.0000000000008976.
10. Raichlin E, Kushwaha S, Daly R, Kremers WK, Frantz R, Clavell A, et al. Combined heart and kidney transplantation provides an excellent survival and decreases risk of cardiac cellular rejection and coronary allograft vasculopathy. Transplant Proc. 2011;43:1871–6.
12. Shen J, Yu W, Chen Q, Shi J, Hu Y, Zhang J, et al. Continuous renal replacement therapy (CRRT) attenuates myocardial inflammation and mitochondrial injury induced by venovenous extracorporeal membrane oxygenation (VV ECMO) in a healthy piglet model. Inflammation. 2013;36:1186–93.
13. Shi J, Chen Q, Yu W, Shen J, Gong J, He C, et al. Continuous renal replacement therapy reduces the systemic and pulmonary inflammation induced by venovenous extracorporeal membrane oxygenation in a porcine model. Artif Organs. 2014;38:215–23.
14. Holaday DA, Smith FR. Clinical characteristics and biotransformation of sevoflurane in healthy human volunteers. Anesthesiology. 1981;54:100–6.
15. Gonsowski CT, Laster MJ, Eger EI, Ferrell LD, Kerschmann RL. Toxicity of compound A in rats. Effect of a 3-hour administration. Anesthesiology. 1994;80:556–65.
16. Teixeira S, Costa G, Costa F, da Silva Viana J, Mota A. Sevoflurane versus isoflurane: does it matter in renal transplantation? Transplant Proc. 2007;39:2486–8.
19. Bellomo R, Wan L, May C. Vasoactive drugs and acute kidney injury. Crit Care Med. 2008;36:S179–86.
20. Schmid S, Jungwirth B. Anaesthesia for renal transplant surgery: an update. Eur J Anaesthesiol. 2012;29:552–8.